Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors

American Journal of Kidney Diseases

Volumn 40, Issue 4, 2002, Pages 728-736

  Paoletti, Ernesto ^a,b   Cassottana, Paolo ^a,b   Bellino, Diego ^a,b   Specchia, Claudia ^a,b   Messa, Piergiorgio ^a,b   Cannella, Giuseppe ^a,b  

^a Sezione di Biostatistica dell Universit   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiotensin converting enzyme (ACE) inhibitors; Cardiovascular events; Hemodialysis (HD); Left ventricular (LV) geometry; Left ventricular hypertrophy (LVH)

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME INHIBITION; FEMALE; FOLLOW UP; GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; MALE; PREDICTION; PULSE PRESSURE; UREMIA; WEIGHT GAIN;

EID: 0036789233     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.35680     Document Type: Article

References (34)

1. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 36:286-290, 1989
2. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996
3. Cannella G, LaCanna G, Sandrini M, et al: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6:31-37, 1991
4. Cannella G, Paoletti E, Delfino R, Peloso GC, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44:881-886, 1993
5. Cannella G, Paoletti E, Barocci S, et al: Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 54:618-626, 1998
6. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345-352, 1991
7. Krumholz HM, Larson M, Levy D: Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 25:879-884, 1995
8. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necroscopy findings. Am J Cardiol 57:450-458, 1986
9. Sargent JA, Gotch FA: Mathematic modeling of dialysis therapy. Kidney Int 18:S2-S11, 1980 (suppl 10)
10. Heyka RJ, Paganini EP: Blood pressure control in chronic dialysis patients, in Maher JF (ed): Replacement of Renal Function by Dialysis (ed 3). Basel, Switzerland, Kluwer, 1989, pp 772-787
11. Cannella G, Paoletti E, Ravera G, et al: Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney Int 58:260-268, 2000
12. Agarwal R, Lewis RR: Prediction of hypertension in chronic hemodialysis patients. Kidney Int 60:1982-1989, 2001
13. O'Rourke RA, Manrath P, Henry WN, et al: Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force: Recommendations for standardization of measurements from M-mode echocardiograms. Circulation 69:854A-857A. 1984
14. Ganau A, Saba PG, Roman MJ, deSimone G, Realdi G, Devereux RB: Ageing induces left ventricular concentric remodelling in normotensive subjects. J Hypertens 13: 1818-1822, 1995
15. Longenecker JC, Coresh J, Klag MJ, et al: Validation of comorbid conditions on the End-Stage Renal Disease Medical Evidence Report: The CHOICE Study. J Am Soc Nephrol 11:520-529, 2000
16. Brahimi M, Dahan M, Dabire H, Levy BI: Impact of pulse pressure on degree of cardiac hypertrophy in patients with chronic uraemia. J Hypertens 18:1645-1650, 2000
17. London GM, Pannier B, Guerin AP. Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
18. Savage T, Giles M, Tomson CV, Raine AEG: Gender differences in mediators of left ventricular hypertrophy in dialysis patients. Clin Nephrol 49:107-112, 1998
19. Smulyan H, Safar ME: The diastolic blood pressure in systolic hypertension. Ann Intern Med 132:233-237, 2000
20. London GM, Pannier B, Vicaut E, et al: Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens 14: 1139-1146, 1996
21. Cannella G, Paoletti E: Clues for understanding the pathogenesis of left ventricular hypertrophy in chronic uremia. Int J Artif Organs 21:378-383, 1998
22. Cannella G, Paoletti E, Delfino R, Peloso GC, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
23. Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 78:197-202, 1996
24. Wachtell K, Smith G, Gerdts E, et al: Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention for Endpoint. Am J Cardiol 85:466-472, 2000
25. Frohlich ED, Apstein C, Chobanian AV, et al: The heart in hypertension. N Engl J Med 327:998-1008, 1992
26. Calderone A, Takahashi N, Izzo NJ, Thaik CM, Colucci WS: Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 92:2385-2390, 1995
27. Wollert KC, Taga T, Saito M, et al: Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. J Biol Chem 271:9535-9545, 1996
28. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5:2024-2031, 1995
29. Cannella G, Albertini A, Assanelli D, et al: Effects of changes in intravascular volume on atrial size and plasma levels of immunoreactive atrial natriuretic peptide in uremic man. Clin Nephrol 30:187-192, 1988
30. Ozkahya M, Ok E, Cirit M, et al: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 13:1489-1493, 1998
31. Reneland R, Andren B, Lind L, Andersson PE, Hanni A, Lithell H: Circulating angiotensin converting enzyme levels are increased in concentric, but not eccentric, left ventricular hypertrophy in elderly men. J Hypertens 15:885-890, 1997
32. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WT: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med 322:1561-1566, 1990
33. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 54:1720-1725, 1998
34. Francis GS: ACE inhibition in cardiovascular disease. N Engl J Med 342:201-202, 2000